Provided by Tiger Trade Technology Pte. Ltd.

Aligos Therapeutics, Inc.

5.86
-1.0500-15.20%
Post-market: 5.870.0100+0.17%18:44 EDT
Volume:98.69K
Turnover:606.79K
Market Cap:36.59M
PE:-0.80
High:6.83
Open:6.83
Low:5.86
Close:6.91
52wk High:13.69
52wk Low:3.98
Shares:6.24M
Float Shares:3.70M
Volume Ratio:1.56
T/O Rate:2.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.3016
EPS(LYR):-2.4500
ROE:-113.59%
ROA:-49.12%
PB:1.15
PE(LYR):-2.39

Loading ...

Aligos reports first interim analysis of B-SUPREME study, fast track designation

TIPRANKS
·
Apr 15

BRIEF-Aligos Therapeutics Announces First Interim Analysis Results From The Phase 2 B-Supreme Study Of Pevifoscorvir Sodium In Participants With Chronic Hepatitis B Virus Infection And Grant Of FDA Fast Track Designation

Reuters
·
Apr 15

Aligos expands Phase 2 B-SUPREME HBeAg- cohort for pevifoscorvir sodium HBV trial

Reuters
·
Apr 15

Aligos Therapeutics Inc - Receives FDA Fast Track Designation for Pevifoscorvir Sodium for Chronic Hepatitis B

THOMSON REUTERS
·
Apr 15

Aligos Therapeutics Inc - Study Drugs Well-Tolerated With No Clinically Concerning Abnormalities

THOMSON REUTERS
·
Apr 15

Aligos Therapeutics Inc - Dsmb Recommends Study Continuation With Increased SAMPLE Size; Futility Criteria Not Met

THOMSON REUTERS
·
Apr 15

Aligos Therapeutics Inc - Topline Data Expected in 2027; Guidance Remains Unchanged

THOMSON REUTERS
·
Apr 15

Aligos Therapeutics Initiated at Buy by WestPark Capital

Dow Jones
·
Mar 26

Aligos Therapeutics Coverage Assumed by Jefferies at Buy

Dow Jones
·
Mar 20

Aligos Therapeutics assumed with a Buy at Jefferies

TIPRANKS
·
Mar 19

Aligos Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 12

Aligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)

TIPRANKS
·
Mar 05

Aligos Therapeutics Q4 EPS $(1.91) Beats $(2.27) Estimate, Sales $169.000K Miss $800.000K Estimate.

Benzinga Earnings
·
Mar 05

Aligos Therapeutics Q4 net loss narrows

Reuters
·
Mar 05

Aligos posts FY 2025 net loss of USD 24.2 million, down 81.6%

Reuters
·
Mar 05

Aligos Therapeutics Q4 Net Income USD -19.881 Million

THOMSON REUTERS
·
Mar 05

Aligos Therapeutics Q4 Income From Operations USD -21.814 Million

THOMSON REUTERS
·
Mar 05

Aligos Therapeutics Q4 Pretax Profit USD -19.851 Million

THOMSON REUTERS
·
Mar 05

Aligos Therapeutics Q4 Operating Expenses USD 21.983 Million

THOMSON REUTERS
·
Mar 05

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire
·
Mar 05